ArticleScientific reports2025
Optimizing post brain death vascularized composite graft quality through ex vivo restoration of S-nitrosothiol homeostasis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
A challenge in vascularized composite allotransplantation (VCA) is mitigating tissue damage within the composite secondary to brain death (BD). Loss of central nervous system function disrupts S-nitrosothiol (SNO) homeostasis to produce systemic hypoxia and ischemic injury during the donor support phase. We reasoned that addition of an S-nitrosylating agent to the preservation solution could correct this damage during ex vivo storage. Employing a swine BD preparation, we excised VC tissues (abdominal blocks and limbs) after a 16-h period of systemic support. The composites were perfused with/without the S-nitrosylating agent ethyl nitrite (ENO) present in the preservation solution. Flow rates and resistance were recorded during the storage period; tissue hypoxia was also quantified. BD decreased circulating SNO levels and reduced tissue oxygenation and muscle protein NO content. During storage, ENO increased flow and decreased resistance within the VCs. Muscle from ENO-treated VCs had lower protein levels of inducible nitric oxide synthase and the hypoxia marker Hif1α and higher levels of the anti-apoptotic protein Bcl2, all suggestive of enhancements of tissue oxygenation. As such, ex vivo S-nitrosylation therapy may be a means to correct BD-induced impairments in SNO-status to improve the quality of composite tissue grafts prior to transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.